Aspire Biopharma shares rise 30.14% intraday after signing CDMO agreement with Microsize for sublingual aspirin development.

Aspire Biopharma surged 30.14% intraday after announcing a partnership with Microsize, a North American CDMO, to develop its lead drug candidate: a 162 mg sublingual aspirin powder for suspected acute myocardial infarction. The collaboration, expected to support a clinical trial and a Section 505(b)(2) New Drug Application submission by late 2026, aligns with Aspire’s strategy to advance existing therapeutics with faster onset and reduced side effects. The CEO emphasized the agreement’s strategic importance, highlighting its role in accelerating U.S.-based innovation and regulatory readiness. The third news item, a generic stock update, contained no actionable details. The partnership’s potential to advance a critical drug candidate and near-term regulatory milestones likely drove the sharp intraday rally.